IHC staining of CD4 in tumor specimens showed that pemetrexed treatment induced a significant increase in the number of CD4+ TILs in tumor areas (figure 3E), suggesting that the tumor cytotoxic effects of pemetrexed may trigger the activation and/or recruitment of CD4+ T helper cells to the tumors. Here, CD4 is linked to neoplasm.